The estimated Net Worth of Christopher Pierce is at least $145 ezer dollars as of 2 September 2021. Christopher Pierce owns over 17,000 units of Prelude Therapeutics Inc stock worth over $103,750 and over the last 4 years Christopher sold PRLD stock worth over $41,186.
Christopher has made over 5 trades of the Prelude Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Christopher exercised 17,000 units of PRLD stock worth $218,450 on 2 September 2021.
The largest trade Christopher's ever made was exercising 17,000 units of Prelude Therapeutics Inc stock on 2 September 2021 worth over $218,450. On average, Christopher trades about 4,179 units every 56 days since 2020. As of 2 September 2021 Christopher still owns at least 20,750 units of Prelude Therapeutics Inc stock.
You can see the complete history of Christopher Pierce stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is C/O PRELUDE THERAPEUTICS INCORPORATED, 200 POWDER MILL ROAD, WILMINGTON, DE, 19803.
Over the last 5 years, insiders at Prelude Therapeutics Inc have traded over $822,895 worth of Prelude Therapeutics Inc stock and bought 5,875,215 units worth $87,687,261 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., David P Bonita és Advisors Llc Orbi Med Capit.... On average, Prelude Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $608,735. The most recent stock trade was executed by Jane Huang on 4 July 2024, trading 9,375 units of PRLD stock currently worth $46,875.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Prelude Therapeutics Inc executives and other stock owners filed with the SEC include: